Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Warren’s bill, dubbed the Affordable Drug Manufacturing Act, would require HHS to publicly manufacture generic drugs “in cases where the market has failed,” and “[strengthen] the market for the long term by jump-starting competition.”
Specifically, the office would be authorized to manufacture a generic drug in a case in which no company is currently manufacturing the product; a case in which only 1 or 2 companies produce the drug, and the price has spiked or the drug is in shortage; or a case in which only 1 or 2 companies produce the drug, the price has created a barrier to patient access, and the World Health Organization has designated the medication as an essential medicine.
“In market after market, competition is dying as a handful of giant companies spend millions to rig the rules, insulate themselves from accountability, and line their pockets at the expense of American families,” said Warren in a statement. “The solution here is not to replace markets, but to fix them. The Affordable Drug Manufacturing Act will introduce more competition into the prescription drug market and bring down prices for consumers.”
The price of insulin has entered the spotlight recently as it is becoming increasingly less affordable, particularly for young adults. Since 2012, the price has more than doubled in the United States. The bill would attempt to address this by requiring the office to begin public production of insulin within 1 year.
Within 1 year of the bill’s enactment, the office will be required to manufacture at least 15 applicable drugs. Additionally, no later than 3 years after the bill is enacted, the office will be required to manufacture or enter into contracts with entities for the manufacturing of at least 25 applicable products.
The introduction of the bill comes on the heels of a letter sent by Warren to Republican colleagues calling for hearings on the recent reports of alleged price-fixing by generic manufacturers in the start of January 2019.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.